ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
Asthma Allergy News
Diabetes News
Women's Health News
 > Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
Guidance Issued for Erectile Dysfunction As Marker of CVD
Erectile dysfunction has predictive value for cardiovascular risk; tx may offer vascular benefits

TUESDAY, July 23 (HealthDay News) -- Erectile dysfunction (ED) has predictive value for cardiovascular risk and treatment may have beneficial effects, according to research published in the June issue of The Journal of Urology.

Noting that ED is a marker of cardiovascular risk, Ajay Nehra, M.D., from the Rush University Medical Center in Chicago, and colleagues conducted a literature review to identify articles relating to the correlations between erectile dysfunction and cardiovascular disease, cardiovascular and all-cause mortality, and pharmacotherapies for dyslipidemia and hypertension. Expertise of a multispecialty investigator group was also incorporated to develop clinical guidance.

The researchers note that risk stratification remains challenging, particularly for patients at low or intermediate short-term risk, even though numerous cardiovascular risk assessment tools exist. The predictive value of ED for cardiovascular events is comparable to or better than that of traditional risk factors. Lifestyle changes can serve as a means of improving overall vascular health and sexual functioning. Erectile function may be positively or negatively affected by statins, diuretics, β-blockers, and renin-angiotensin system modifiers. In addition, there may be systemic vascular benefits from phosphodiesterase type 5 inhibitors used to treat ED.

"It is the responsibility of the primary care physician and urologist to address sexual function in men who present with ED and also initiate treatment plans that improve the overall vascular health of patients with ED," the authors write.

This study was partially supported by Pfizer.

Abstract
Full Text (subscription or payment may be required)



Health News Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS